Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Sierra Oncology Inc is a biotechnology business based in the US. Sierra Oncology shares (SRRA) are listed on the NASDAQ and all prices are listed in US Dollars. Sierra Oncology employs 109 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $54.99 |
|---|---|
| 52-week range | $14.91 - $55.19 |
| 50-day moving average | $54.73 |
| 200-day moving average | $33.52 |
| Wall St. target price | $55.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-6.59 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $54.99 from 2022-07-01
| 1 week (2022-06-24) | 0.15% |
|---|---|
| 1 month (2022-05-29) | N/A |
| 3 months (2022-03-31) | 71.58% |
| 6 months (2021-12-31) | 152.94% |
| 1 year (2021-07-02) | 178.43% |
|---|---|
| 2 years (2020-07-02) | 360.17% |
| 3 years (2019-07-02) | 10,100.33% |
| 5 years (2017-06-30) | 4,600.00% |
| Revenue TTM | $200,000 |
|---|---|
| Gross profit TTM | $-59,953,000 |
| Return on assets TTM | -32.85% |
| Return on equity TTM | -56.54% |
| Profit margin | 0% |
| Book value | $10.99 |
| Market capitalisation | $1.3 billion |
TTM: trailing 12 months
We're not expecting Sierra Oncology to pay a dividend over the next 12 months.
Sierra Oncology's shares were split on a 1:40 basis on 22 January 2020. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sierra Oncology shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Sierra Oncology shares which in turn could have impacted Sierra Oncology's share price.
Over the last 12 months, Sierra Oncology's shares have ranged in value from as little as $14.91 up to $55.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sierra Oncology's is 0.0154. This would suggest that Sierra Oncology's shares are less volatile than average (for this exchange).
Sierra Oncology, Inc. , a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.